• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与西卡宁相关的菖蒲烷半萜类化合物:生物活性与合成

Siccanin-related drimane meroterpenoids: biological activities and synthesis.

作者信息

Sun Shengxin, Wang Xia, Hu Nvdan, Fu Shiqi, Li Shengkun

机构信息

State Key Laboratory of Green Pesticide, Center for R&D of Fine Chemicals of Guizhou University, Guiyang, 550025, China.

出版信息

Nat Prod Rep. 2025 Jan 22;42(1):113-150. doi: 10.1039/d4np00025k.

DOI:10.1039/d4np00025k
PMID:39494729
Abstract

Covering: 1962 to 2023Drimane (hydro)quinones biosynthetically arise from the combination of drimane-type terpenoids with phenols or equivalents. Since the isolation of siccanin in 1962 (structure identified in 1967), over 200 natural drimane (hydro)quinones have been reported. They are widespread with remarkably diverse architectures and biological functions, which are achieved by varying either the drimane subunit, hydroquinone segment, or the fusion types of drimane and hydroquinone segment both of them. This type of natural products has drawn increasing attention in the discovery of novel pharmaceutical leads. Enormous efforts have been devoted to developing efficient and divergent synthesis approaches to facilitate the SAR study of drimane (hydro)quinones, aiming for more promising functional leads. This review is arranged mainly in terms of scaffold types of drimane (hydro)quinones and further categorized on the basis of biological functions. The mechanisms of action are also briefly discussed. Synthetic methods are categorized according to the strategies forging the Csp-Csp linker between drimane segments and (hydro)quinone subunits.

摘要

涵盖时间

1962年至2023年

杜松烷(氢)醌通过杜松烷型萜类化合物与酚类或类似物的结合生物合成产生。自1962年分离出西卡宁(1967年确定其结构)以来,已报道了200多种天然杜松烷(氢)醌。它们分布广泛,具有极为多样的结构和生物学功能,这些功能通过改变杜松烷亚基、对苯二酚片段或者杜松烷和对苯二酚片段二者的融合类型来实现。这类天然产物在新型药物先导物的发现中受到越来越多的关注。人们付出了巨大努力来开发高效且多样的合成方法,以促进对杜松烷(氢)醌的构效关系研究,从而寻找更有前景的功能性先导物。本综述主要按照杜松烷(氢)醌的骨架类型进行编排,并根据生物学功能进一步分类。还简要讨论了其作用机制。合成方法根据在杜松烷片段和(氢)醌亚基之间构建Csp-Csp连接键的策略进行分类。

相似文献

1
Siccanin-related drimane meroterpenoids: biological activities and synthesis.与西卡宁相关的菖蒲烷半萜类化合物:生物活性与合成
Nat Prod Rep. 2025 Jan 22;42(1):113-150. doi: 10.1039/d4np00025k.
2
Short-Term Memory Impairment短期记忆障碍
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
5
Updates on Intrinsic Medicinal Chemistry of 1,4-dihydropyridines, Perspectives on Synthesis and Pharmacokinetics of Novel 1,4-dihydropyrimidines as Calcium Channel Blockers: Clinical Pharmacology.1,4 - 二氢吡啶的内在药物化学进展,新型1,4 - 二氢嘧啶作为钙通道阻滞剂的合成与药代动力学展望:临床药理学
Curr Top Med Chem. 2025 Jan 1. doi: 10.2174/0115680266323908241114064318.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
7
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.